In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...

Leading scientists are advocating for annual prostate cancer screening for men with BRCA1 and BRCA2 gene mutations. Experts at the London-based Institute of Cancer Research (ICR) state that the ...

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...

Expanded indication for AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...

Figure 1: Photograph of agarose gel electrophoresis showing PCR-RFLP of BRCA2 and HOXB13 gene mutation mentioned in Table 1. (A) Here P1, P3, and P4 shows the positive results for BRCA2 gene mutation.

Prostate cancer screening should not be made routinely available for the vast majority of men in the UK, a committee advising the Government has said. In a draft recommendation, the UK National ...

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* By Johnson & ...

The UK National Screening Committee (UK NSC) is poised to deliver its recommendations to the Government on Friday regarding expanded prostate cancer screening for men. Currently, the UK lacks a ...

Genetic screening for prostate cancer can help identify inherited risks early, guide treatment decisions, and protect your family’s health. At Fred Hutch Cancer Center, we offer expert genetic ...